Emkay Investment Managers Ltd. (EIML) is the asset Management arm of Emkay Global Financial Services Ltd. (EGFSL), a SEBI registered Portfolio Manager managing & advising investments for long-term (3-5 years+) investors consisting of Family Offices, HNIs, Corporate & NRIs, in Indian equities.

## August 2026 Market Commentary

August began on a cautious but relatively constructive note, with markets supported by hopes of easing US-Iran tensions, a stable domestic macro backdrop and the RBI keeping the **repo rate unchanged at 5.25%** for the fourth consecutive meeting. However, elevated crude prices and continued uncertainty around global trade and geopolitics kept investors watchful. A significant shift was visible in foreign flows: **FPIs turned net buyers for the second consecutive month, investing ₹23,000 crore (cash + futures) in Indian equities in August,** following ₹24,701 crore in July and marking the first two-month buying streak after four consecutive months of heavy selling. Despite this turnaround, FPIs remained net sellers by around **₹3.20 lakh crore (cash + futures) in CY2026**, highlighting that the August inflow was an early sign of improving sentiment rather than a complete reversal of the broader trend.

By mid-August, markets remained range-bound as renewed geopolitical concerns and higher crude prices weighed on sentiment, with the **Nifty 50 declining for six consecutive sessions** at one point. Brent crude moved above **US$90/bbl,** while the rupee weakened toward **₹95.70/USD.** At the same time, market leadership increasingly shifted towards the broader market. Sector performance during August was mixed, with **Capital Goods (+2.9%), Metals (+2.4%)**, and **Healthcare (+1.5%)** emerging as the key outperformers. On the other hand, **FMCG (-4.1%)** and **Power (-3.3%)** were the biggest laggards. Toward month-end, Indian equities remained under pressure as geopolitical tensions resurfaced and concerns around US interest rates weighed on risk appetite. The **Nifty 50 fell 1.2% and the Sensex 1.5% in August**, snapping their two-month winning streak. In contrast, the broader market remained resilient, with the **Nifty Midcap 150 gaining 1.7% and Nifty Smallcap 250 rising 2.5%**, marking their **fifth consecutive month of gains**. This continued divergence highlighted the relative strength of mid- and small-cap stocks, supported by domestic liquidity, even as large caps remained more sensitive to global flows. By month-end, the **rupee stood at around ₹95.56/USD**, while crude had moderated from its mid-month highs, offering some relief. Markets entered September with a **cautious but not bearish** sentiment, supported by improving FPI flows and strong domestic liquidity, although geopolitical developments and global rates remained key risks.

## E-Qual Framework

- Arguably, the only framework of its kind in India
- Framework under active implementation for the last 10 years
- Zero exposure to managements with low corporate governance across portfolios

FORTIFIED WITH E-QUAL

What does the E-Qual framework constitute?

- Calculate Qualitative Parameters – Objectively
- Capture publicly available data points and weigh them to create a ranking
- Sorting of Companies on Relative Ranking of Market Capitalization

| | |
|---|---|
| Management Integrity | 40% |
| Management Capability | 30% |
| Wealth Distribution | 15% |
| Investor Communication | 7.50% |
| Liquidity | 7.50% |



# Emkay Capital Builder

FORTIFIED WITH E-QUAL

Emkay Your success is our success | Investment Managers

## Sectors




## Top 5 holdings

DIVI'S LABORATORIES LTD

ICICI BANK LTD

HDFC BANK LTD

THE FEDERAL BANK LTD

ETERNAL LTD

## Market Capitalisation




## Performance Update

| | 1M | 3M | 6M | 1Y | 2Y | 3Y | 5Y | FYTD | Since April 1, 2013 (13.4 Years)* CAGR | Total Returns |
|---|---|---|---|---|---|---|---|---|---|---|
| CAPITAL BUILDER - TWRR | 2.0 | 14.2 | 8.5 | 11.6 | 8.0 | 17.2 | 15.6 | 22.3 | 16.4 | 668.2 |
| BSE 500 TRI | -0.1 | 3.9 | 1.4 | 4.7 | -0.1 | 12.1 | 10.9 | 14.5 | 14.5 | 514.3 |
| Nifty 50 TRI | -1.1 | 2.9 | -3.6 | -0.4 | -1.2 | 9.0 | 8.3 | 8.7 | 12.7 | 400.0 |

As on 31.08.2026

Emkay Capital Builder PMS strategy is benchmarked against the S&P BSE 500 TRI.
The Nifty 50 TRI is presented solely for additional comparative insight and should not be construed as an official benchmark.
Performance related information provided here is not verified by SEBI
*The current Portfolio Manager is managing since April 1, 2013
For period >1 year, CAGR returns are presented
Net of Fees & Expenses

Benchmark **BSE 500 TRI**

Total number of Stocks **18-20**

**FLEXI CAP**

Average Marketcap INR **2,87,624** Cr

As on 31.08.2026

**Note :** The current portfolio holdings may or may not be a part of the future portfolio holdings.
Investor's Portfolio may vary from the Strategy Level Portfolio shown above in the Top Holdings.
(Above Portfolio details are as on 31.08.2026

## August 2026 Portfolio Commentary

**The Capital Builder Strategy** generated a return of **2.0%** in August 2026, compared to **-0.1%** delivered by the BSE 500 TRI.

**Key Contributors:**

**DIVI'S LABORATORIES** shares gained **14.8%** on strong Q1 FY27 performance, with revenue up **28%** and PAT up **66%**, reinforcing expectations of sustained growth in its API and CDMO businesses.

**SUNDRAM FASTENERS** rose **23.4%** as strong Q1 performance, improving exports, and a healthy project pipeline boosted confidence in the company's growth outlook.

**AKUMS DRUGS & PHARMACEUTICALS** advanced **17.9%** following strong Q1 results, with EBITDA up **35%** and PAT up **55%**, driven by robust CDMO performance and a positive re-rating.

**Key Detractors:**

**GODREJ CONSUMER PRODUCTS** declined **15.6%** after the sudden CEO resignation raised concerns around execution and strategic continuity, triggering a sharp sell-off.

**HDFC BANK** fell **5.2%** as uncertainty around CEO succession, following Sashidhar Jagdishan's decision not to seek another term, weighed on investor sentiment.

FUND MANAGEMENT TEAM

| | |
|---|---|
| **Sachin Shah** | Executive Director and Fund Manager |
| **Kashyap Javeri** | Head of Research & Co-Fund Manager |

Emkay New Vitalised India Strategy

FORTIFIED WITH E-QUAL

Emkay Your success is our success | Investment Managers

## Sectors




## Top 5 holdings

- DIVI S LABORATORIES LTD
- EICHER MOTORS LTD
- AKUMS DRUGS AND PHARMACEUTICALS LTD
- SANSERA ENGINEERING LTD
- DIVGI TORQTRANSFER SYSTEMS LTD

* Model Portfolio

## Market Capitalisation




## Performance Update

| | 1M | 3M | 6M | 1Y | 2Y | 3Y | FYTD | Since Inception (CAGR) | Total Returns |
|---|---|---|---|---|---|---|---|---|---|
| ENVI - TWRR | 5.2 | 13.9 | 19.7 | 26.0 | 10.3 | 17.0 | 34.4 | 24.0 | 147.8 |
| BSE 500 TRI | -0.1 | 3.9 | 1.4 | 4.7 | -0.1 | 12.1 | 14.5 | 14.2 | 75.4 |

Since Inception Date : 13th Jun 2022

As on 31.08.2026

**Performance related information provided here is not verified by SEBI**

Net of Fees & Expenses

Benchmark **BSE 500 TRI**

Total number of Stocks **15-20**

**FLEXI CAP**

Average Marketcap INR **99,893** Cr

As on 31.08.2026

Note: The current portfolio holdings may or may not be a part of the future portfolio holdings.
Investors' Portfolio may vary from the Strategy Level Portfolio shown above in the Top Holdings.
(Above Portfolio details are as on 31.08.2026)

## August 2026 Portfolio Commentary

The **ENVI strategy** delivered a return of **5.2%** in August 2026, outperforming the **BSE 500 TRI**, which declined **-0.1%.**

**Key contributors:**

**SANSERA ENGINEERING** shares gained **20.2%** on strong Q1 earnings and continued traction across aerospace, industrial, and premium auto segments, improving confidence in its growth trajectory.

**DIVGI TORQTRANSFER SYSTEMS** rose **23.0%** following exceptional Q1 performance, with revenue up **91%** and PAT up **183% YoY**, driving a sharp positive re-rating.

**AKUMS DRUGS & PHARMACEUTICALS** advanced **17.9%** after strong Q1 results, with EBITDA up **35%** and PAT up **55%**, driven by robust CDMO performance and triggering a positive re-rating.

**DIVI'S LABORATORIES** gained **14.8%** on strong Q1 FY27 performance, with revenue up **28%** and PAT up **66%**, reinforcing expectations of sustained growth in its API and CDMO businesses.

**GMM PFAUDLER** rose **21.1%** as strong order intake and a healthy order backlog improved revenue visibility and boosted investor confidence.

**Key detractors:**

**GODREJ CONSUMER PRODUCTS** declined **15.6%** after the sudden CEO resignation raised concerns around execution and strategic continuity, triggering a sharp sell-off.

**PI INDUSTRIES** fell **12.8%** following weak Q1 performance, with declines in revenue and PBT highlighting continued pressure in the agrochemical business.

FUND MANAGEMENT TEAM

| | |
|---|---|
| **Kashyap Javeri** | Head of Research and Fund Manager |
| **Sachin Shah** | Executive Director and Co-Fund Manager |

# Emkay SMID Cap Growth Engine Portfolio

FORTIFIED WITH E-QUAL

Emkay Your success is our success | Investment Managers

## Sectors




FINANCIAL SERVICES · CAPITAL GOODS · IT · HEALTHCARE · REAL ESTATE · OTHERS

## Top 5 holdings

| |
|---|
| AEGIS VOPAK TERMINALS LTD |
| INDUSIND BANK LTD |
| MAX FINANCIAL SERV LTD |
| STYRENIX PERFORMANCE MATERIALS LTD |
| LUMAX AUTO TECH LTD |

* Model Portfolio

## Market Capitalisation




Small Cap · Mid Cap

## Performance Update

| | 1M | 3M | 6M | 1Y | FYTD | Since Inception* (CAGR) | Total Returns |
|---|---|---|---|---|---|---|---|
| SMID CAP GROWTH ENGINE PORTFOLIO - TWRR | 1.2 | 9.6 | 13.7 | 3.1 | 32.3 | -0.9 | -1.2 |
| BSE 500 TRI | -0.1 | 3.9 | 1.4 | 4.7 | 14.5 | 1.8 | 2.2 |
| BSE 250 SmallCap TRI | 2.5 | 7.0 | 15.1 | 9.9 | 28.4 | 4.7 | 5.9 |

Since Inception Date : 9th June 2025

As on 31.08.2026

Perfromance related information provided here is not verified by sebi
Emkay SMID PMS strategy is benchmarked against the S&P BSE 500 TRI.
The BSE 250 SmallCap TRI is presented solely for additional comparative insight and should not be construed as an official benchmark
Net of Fees & Expenses
*Absolute

Benchmark **BSE 500 TRI**

Total number of Stocks **25-35**

**SMALL & MID CAP**

Average Marketcap INR **24,034** Cr

As on 31.08.2026

Note: The current portfolio holdings may or may not be a part of the future portfolio holdings.
Investors' Portfolio may vary from the Strategy Level Portfolio shown above in the Top Holdings.
(Above Portfolio details are as on 31.08.2026)

## August 2026 Portfolio Commentary

**Emkay SMIDCap Growth Engine Strategy d**elivered a return of **1.2%** in August 2026, while the **BSE 500 TRI** and **BSE Smallcap 250 TRI** delivered returns of **-0.1%** and **2.5%,** respectively during the month.

**Key contributors:**

**LUMAX AUTO TECHNOLOGIES** shares gained **32.8%** on strong Q1 results, with revenue up **33%** and PAT up **83%,** alongside a healthy order book, driving the sharp rally.

**PINE LABS** rose **18.4%** as positive investor sentiment around its growth trajectory and strong appetite for the recently listed fintech supported the stock.

**ENGINEERS INDIA** advanced **17.8%** following strong Q1 profitability and significant margin expansion, reinforcing confidence in its higher-margin, consultancy-led growth.

**MAHARASHTRA SEAMLESS** gained **16.9%** on strong Q1 PAT growth and a healthy order pipeline, despite some pressure on operating margins.

**Key detractors:**

**STYRENIX PERFORMANCE MATERIALS** declined **18.9%** due to profit-booking after a strong run-up and valuation concerns, despite strong Q1 earnings.

FUND MANAGEMENT TEAM

| | |
|---|---|
| **Manish Sonthalia** | Director and CIO |
| **Kashyap Javeri** | Head of Research and Co-Fund Manager |